Home / Health / FDA Greenlights Promising Aplastic Anemia Therapy Trial
FDA Greenlights Promising Aplastic Anemia Therapy Trial
28 Apr
Summary
- FDA cleared Phase II trial for aplastic anemia treatment CK0801.
- Trial targets patients refractory to prior therapies or transfusion-dependent.
- Primary endpoint is a 30% reduction in transfusion needs by day 180.
Cellenkos has received FDA clearance to initiate a Phase II clinical trial for CK0801, a novel therapy aimed at treating aplastic anemia. This open-label, multi-center study will evaluate the safety and clinical activity of CK0801 in adult patients. The trial specifically includes individuals who are refractory to prior therapies, intolerant to standard treatments, or dependent on red blood cell and/or platelet transfusions.
The primary objective of the Phase II trial is to achieve a 30% reduction in transfusion requirements by day 180. CK0801 utilizes Cellenkos' CRANE technology, designed to address bone marrow inflammation and restore immune balance. Previous Phase I findings, published in NEJM Evidence in 2024, demonstrated a favorable safety profile and early signs of durable clinical activity, with some patients achieving long-term transfusion independence.
